Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Depomed, Inc.
Type
Public company
Traded as NASDAQ: DEPO
S&P 600 Component
Industry Pharmaceutical Industry
Founded 1995 (1995)
Headquarters Newark, California
Products Pharmaceuticals
Revenue DecreaseUS$342.7 million (2015)
Operating income
DecreaseUS$-50.4 million (2015)
Net income
DecreaseUS$-75.7 million (2015)
Total assets IncreaseUS$1.3 billion (2015)
Total equity DecreaseUS$315 million (2015)
Number of employees
494 (December 2015)
Website www.depomed.com

Depomed, Inc. is an American specialty pharmaceutical company which mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. The company is a publicly traded company on NASDAQ under the symbol "DEPO", with several products approved by the United States Food and Drug Administration (FDA).

The company's products include Nucynta ER, Nucynta, Gralise, Cambia, Lazanda, Zipsor, and DM-1992, which mainly focus on pain, neuropathic pain, and central nervous system diseases.

Nucynta ER, Nucynta IR

On January 15, 2015, Depomed announced the acquisition of the Nucynta franchise from Janssen Pharmaceutica for US$1,050,000,000 in cash. The transaction closed on April 2, 2015, and the products are scheduled to be relaunched in June 2015 after a major salesforce expansion.

Gralise

In January 2011, Gralise once-daily (gabapentin extended release) was approved by the US FDA for the treatment of postherpetic neuralgia. The drug has also received Orphan Drug designation from the FDA.

The company's diabetes treatment, Glumetza (metformin hydrochloride extended release tablet), was approved for the treatment of type II diabetes in adults, and is sold in the US by Valeant.

In June 2012, all rights to Zipsor Liquid Filled Capsules was acquired by Depomed from Xanodyne Pharmaceuticals, revenue generated by Zipsor was approximately US$19,000,000 as within the twelve months from Jun 2011 to May 2012.

In March 2012, the company filed a patent infringement lawsuit against three companies that had filed Abbreviated New Drug Applications with the US FDA, claiming infringement of Depomed's six US patents listed for Gralise in the FDA's Orange Book.

Investment goal date:
Dividends reinvested
Depomed, Inc. DEPO report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-08
--
--
Q4 2017
2018-02-22
--
--
Q4 2017
2018-02-19
--
--
Q3 2017
2017-11-07
0.1400
-0.2500
Q3 2017
2017-11-06
--
--
Q2 2017
2017-08-07
0.0800
-0.4300
Q1 2017
2017-05-09
0.0700
-0.4300
Q4 2016
2017-02-21
0.3000
-0.7200
Q3 2016
2016-11-07
0.1700
-0.2100
Q2 2016
2016-08-03
0.1900
-0.1700
Q1 2016
2016-05-05
0.0500
-0.3400
Q4 2015
2016-02-22
0.1600
-0.5100
Q3 2015
2015-11-09
0.3300
-0.2000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BlackRock Fund Advisors
6153509
BlackRock Inc.
8869139
BlackRock Institutional Trust Company, N.A.
1596879
DELTEC ASSET MANAGEMENT LLC
1075342
DIMENSIONAL FUND ADVISORS LP
1242450
HighTower Advisors, LLC
892028
Invesco Ltd.
2083017
Litespeed Management LLC
1833698
NORTHERN TRUST CORP
787201
OAK RIDGE INVESTMENTS LLC
2382409
PRICE T ROWE ASSOCIATES INC /MD/
898298
RIMA SENVEST MANAGEMENT, L.L.C.
5400005
Starboard Value LP
5295270
STATE STREET CORP
2374915
Vanguard Group, Inc
4791200
Major Shareholders
Name Relationship
Total Shares
Holding stocks
HIGGINS ARTHUR J
0.0300% (15000)
DEPO / ECL / ENDP / ZMH /
BURRILL STEVEN
0.0700% (40000)
DEPO / TRGT /
ANIDO VICENTE JR
0.0100% (4403)
AERI / DEPO /
LAVIGNE LOUIS J JR
0.0100% (4403)
AGN / ARAY / DEPO / ZNGA /
STERN JULIAN N
0.3600% (208333)
DEPO / FGEN /
DAWES KAREN A
0.0200% (12867)
DEPO / PDLI / RGEN /
STAPLE PETER D
0.1700% (99403)
DEPO /
Zenoff David B
0.1600% (93999)
DEPO / EXAM /
Moretti August J
0.0700% (41785)
ALXA / DEPO /
Saks Samuel R
0.0100% (5099)
ASPX / DEPO / PDLI / TNXP /
Gosling Matthew M
0.0400% (20665)
DEPO /
Cameron Tammy
0.0100% (3960)
DEPO /
Srinivas Rao
0.0300% (19527)
DEPO /
Sweeney Michael MD
0.0200% (9084)
DEPO /
% ()